Related references
Note: Only part of the references are listed.Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
Reinhard Dummer et al.
EUROPEAN JOURNAL OF CANCER (2014)
Cutis Verticis Gyrata in Association With Vemurafenib and Whole-Brain Radiotherapy
James J. Harding et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
Laura Ridolfi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur et al.
LANCET ONCOLOGY (2014)
Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib
Andrea Forschner et al.
MELANOMA RESEARCH (2014)
Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports
B. Schulze et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2014)
Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia
Nina Lang et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2014)
Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy
Ricarda Merten et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2014)
Cutaneous effects of BRAF inhibitor therapy: a case series
P. L. Mattei et al.
ANNALS OF ONCOLOGY (2013)
Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas
Tina Dasgupta et al.
INVESTIGATIONAL NEW DRUGS (2013)
Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma
Christopher J. Anker et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy
Imke Satzger et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity
Natalia Rompoti et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Vemurafenib and radiation therapy in melanoma brain metastases
Ashwatha Narayana et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Paradoxical oncogenesis: are all BRAF inhibitors equal?
Alexander M. Menzies et al.
PIGMENT CELL & MELANOMA RESEARCH (2013)
Melanoma brain metastasis: overview of current management and emerging targeted therapies
Ekokobe Fonkem et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long et al.
LANCET ONCOLOGY (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032
Maria J. Sambade et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients
Luitpold V. R. Distel et al.
RADIOTHERAPY AND ONCOLOGY (2006)
Cytogenetic instability in young patients with multiple primary cancers
U Keller et al.
CANCER GENETICS AND CYTOGENETICS (2005)
Radiation sensitivity testing by fluorescence in-situ hybridization:: how many metaphases have to be analysed?
U Keller et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2004)
A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of maliqnant melanoma
F Mornex et al.
MELANOMA RESEARCH (2003)